138 related articles for article (PubMed ID: 7717988)
21. Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and
Krebs SK; Stech M; Jorde F; Rakotoarinoro N; Ramm F; Marinoff S; Bahrke S; Danielczyk A; Wüstenhagen DA; Kubick S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430170
[TBL] [Abstract][Full Text] [Related]
22. Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?
Dicks LMT; Vermeulen W
Microorganisms; 2022 Aug; 10(9):. PubMed ID: 36144335
[TBL] [Abstract][Full Text] [Related]
23. Reduced cytotoxicity by mutation of lysine 590 of
Ammon A; Mellenthin L; Emmerich C; Naschberger E; Stürzl M; Mackensen A; Müller F
Immunother Adv; 2022; 2(1):ltac007. PubMed ID: 35919491
[TBL] [Abstract][Full Text] [Related]
24.
Havaei SM; Aucoin MG; Jahanian-Najafabadi A
Front Oncol; 2021; 11():781800. PubMed ID: 34976821
[TBL] [Abstract][Full Text] [Related]
25. Immunotoxins: From Design to Clinical Application.
Kreitman RJ; Pastan I
Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827694
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
Kreitman RJ; Arons E
Blood Rev; 2022 Jan; 51():100888. PubMed ID: 34535326
[TBL] [Abstract][Full Text] [Related]
27. Cell Death Signaling Pathway Induced by Cholix Toxin, a Cytotoxin and eEF2 ADP-Ribosyltransferase Produced by
Ogura K; Yahiro K; Moss J
Toxins (Basel); 2020 Dec; 13(1):. PubMed ID: 33374361
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic Mechanisms in Irritable Bowel Syndrome.
Mahurkar-Joshi S; Chang L
Front Psychiatry; 2020; 11():805. PubMed ID: 32922317
[TBL] [Abstract][Full Text] [Related]
29. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
[TBL] [Abstract][Full Text] [Related]
30. Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors.
Oh F; Modiano JF; Bachanova V; Vallera DA
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32630411
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of Resistance to Immunotoxins Containing
Dieffenbach M; Pastan I
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32630017
[TBL] [Abstract][Full Text] [Related]
32. Crystal Structure of Exotoxin A from
Masuyer G
Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32549399
[No Abstract] [Full Text] [Related]
33. Study on the targeted therapy of oral squamous cell carcinoma with a plasmid expressing PE38KDEL toxin under control of the SERPINB3 promoter.
Wu J; Guo Q; Zhang G; Zhao L; Lv Y; Wang J; Liu J; Shi W
Cancer Med; 2020 Mar; 9(6):2213-2222. PubMed ID: 32017381
[TBL] [Abstract][Full Text] [Related]
34. Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma.
Zhu S; Chen J; Xiong Y; Kamara S; Gu M; Tang W; Chen S; Dong H; Xue X; Zheng ZM; Zhang L
PLoS Pathog; 2020 Jan; 16(1):e1008223. PubMed ID: 31905218
[TBL] [Abstract][Full Text] [Related]
35. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
[TBL] [Abstract][Full Text] [Related]
36. Toxins Utilize the Endoplasmic Reticulum-Associated Protein Degradation Pathway in Their Intoxication Process.
Nowakowska-Gołacka J; Sominka H; Sowa-Rogozińska N; Słomińska-Wojewódzka M
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875878
[TBL] [Abstract][Full Text] [Related]
37. A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer.
Jiang P; Wang L; Hou B; Zhu J; Zhou M; Jiang J; Wang L; Chen S; Zhu S; Chen J; Zhang L
Theranostics; 2018; 8(13):3544-3558. PubMed ID: 30026865
[TBL] [Abstract][Full Text] [Related]
38.
Langari J; Karimipoor M; Golkar M; Khanahmad H; Zeinali S; Omidinia S; Cohan RA; Behdani M; Babaie J; Arezumand R; Moazami R
Adv Biomed Res; 2017; 6():144. PubMed ID: 29226113
[TBL] [Abstract][Full Text] [Related]
39. Clinical targeting recombinant immunotoxins for cancer therapy.
Li M; Liu ZS; Liu XL; Hui Q; Lu SY; Qu LL; Li YS; Zhou Y; Ren HL; Hu P
Onco Targets Ther; 2017; 10():3645-3665. PubMed ID: 28790855
[TBL] [Abstract][Full Text] [Related]
40. Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro.
Deng C; Xiong J; Gu X; Chen X; Wu S; Wang Z; Wang D; Tu J; Xie J
Oncotarget; 2017 Jun; 8(24):38568-38580. PubMed ID: 28445134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
